Bottle Label 20 mg (71610 0567 04)
Tadalafil Tablet, Film Coated
Product Images NDC 71610-567
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71610-567). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena Pharma Solutions (TN)
10 (Tadalafil Tablets Usp 1)
10 (Tadalafil Tablets Usp 2)
This appears to be a table of data showing the difference between Tadalafil (a medication for erectile dysfunction) and a placebo in terms of blood pressure measurements. The table shows the difference in standing systolic and diastolic blood pressure, as well as supine systolic and diastolic blood pressure, over time (in hours). However, the data is incomplete and not readable without additional context.*
10 (Tadalafil Tablets Usp 3)
10 (Tadalafil Tablets Usp 4)
This is a medication experiment involving tadalafil and doxazosin. Different doses of tadalafil and doxazosin were given at 8:00 AM to individuals, along with a placebo as a control variable. The experiment monitored systolic blood pressure changes over time. The results of the experiment are not provided.*
10 (Tadalafil Tablets Usp 5)
This is a graph showing the plasma concentration of Tadalafil in mcg/L over time in hours after administration of various doses of the drug. The graph includes a single 20mg dose, a single 5mg dose, and a once-daily 5mg dose following 5 consecutive days of administration. The concentration of plasma Tadalafil increases over time and peaks at different levels depending on the dosage.*
10 (Tadalafil Tablets Usp 6)
This is a graph that shows the change from baseline in IPSS total score for two treatment groups over the course of a certain number of weeks. One group was treated with tadalafil 5 mg and the other group was treated with a placebo. At the end of the treatment period, the difference in scores between the two groups was statistically significant with a p-value of less than 0.01. The duration of treatment in weeks is not specified.*
10 (Tadalafil Tablets Usp 7)
The text is a comparison of the effects of Tadalafil 5mg and placebo on IPSS total score. The data shows a significant improvement in IPSS total score for Tadalafil 5mg compared to placebo. The duration of treatment in weeks is not specified.*
10 (Tadalafil Tablets Usp 8)
10 (Tadalafil Tablets Usp 9)
The text represents a comparison of the effects of Tadalafil 5mg and a Placebo in the treatment of a medical condition. The data includes the change from the baseline in IPSS Total Score as the outcome measure. There is also a statistical value of "p<0.01" which indicates the level of significance. However, without additional information or context, the specific medical condition or study design is not available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
